本文通过系统评价和荟萃分析，研究 PI-RADS 2.1 升级规则对前列腺移行带（TZ）病变中前列腺癌（PCa）检出率的影响。发现 “2 + 1” 和 “3 + 1” 病变的癌症风险符合评分系统，但假阳性率高，对活检决策意义重大。 研究背景 磁共振成像（MRI）在前列腺癌（PCa）的 ...

前列腺MRI靶向活检阴性患者的后续癌症检测率低，临床意义前列腺癌罕见，尤其PI-RADS 3组未检出癌症。基于PI-RADS分类、PSA密度和DRE结果的风险分层管理可减少重复活检需求。 对于PI-RADS 3–5级病变的男性患者，在MRI引导的活检结果为阴性后的最佳随访方案仍存在 ...

Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs). This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...

Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not include a ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...